<DOC>
	<DOCNO>NCT00020150</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine temozolomide O6-benzylguanine treat child solid tumor respond previous therapy .</brief_summary>
	<brief_title>Temozolomide O6-benzylguanine Treating Children With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose temozolomide administer biologically active dose O6-benzylguanine ( O6-BG ) child refractory solid tumor . - Determine dose-limiting toxicity toxicity profile combination patient . - Assess plasma pharmacokinetics O6-BG active metabolite , 8-oxo-O6-BG , patient . - Assess plasma pharmacokinetics combination patient . - Correlate level alanine-glyoxylate aminotransferase peripheral blood mononuclear cell degree hematologic toxicity combination patient . OUTLINE : This dose-escalation study . Patients receive O6-benzylguanine ( O6-BG ) IV 1 hour follow 30 minute later oral temozolomide daily 5 day . Treatment continue every 28 day 12 course absence unacceptable toxicity disease progression . Sequential dose escalation O6-BG follow sequential dose escalation temozolomide . Cohorts 3-6 patient receive escalate dos O6-BG temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 6 patient experience dose-limiting toxicity . Quality life assess baseline prior course 1 , 3 , 6 , 8 , 12 . PROJECTED ACCRUAL : A total 21-48 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor refractory standard therapy potentially curative therapy exists , include , limited : Rhabdomyosarcoma soft tissue sarcomas Ewing 's family tumor Osteosarcoma Neuroblastoma Wilms ' tumor Hepatic tumor Germ cell tumor Primary brain tumor Histological confirmation may waive brainstem optic glioma Measurable evaluable disease Evidence progressive disease prior chemotherapy radiotherapy persistent disease prior surgery PATIENT CHARACTERISTICS : Age : 21 Performance status : ECOG 02 Life expectancy : At least 8 week Hematopoietic : Absolute granulocyte count great 1,500/mm^3 Hemoglobin great 8 g/dL Platelet count great 100,000/mm^3 Hepatic : Bilirubin normal SGPT le 2 time upper limit normal No significant hepatic dysfunction Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No significant cardiac dysfunction Pulmonary : No significant pulmonary dysfunction Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able swallow capsule No significant unrelated systemic illness would preclude study ( e.g. , serious infection organ dysfunction ) No prior hypersensitivity dacarbazine , temozolomide , polyethylene glycol PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior colonystimulating factor ( e.g. , filgrastim [ G CSF ] , sargramostim [ GMCSF ] , epoetin alfa ) At least 4 month since prior myeloablative therapy require bone marrow stem cell transplantation No concurrent anticancer immunotherapy Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 4 week nitrosoureas ) recover Prior temozolomide allow provide administer within past 3 month , severe toxicity experience prior course , give combination agent design inactivate alanineglyoxylate aminotransferase No concurrent investigational standard anticancer chemotherapy Endocrine therapy : Concurrent corticosteroid control brain tumorassociated edema allow provide stable decrease dose least 1 week prior study Radiotherapy : See Disease Characteristics At least 4 week since prior limitedfield radiotherapy At least 4 month since prior craniospinal irradiation , total body irradiation , radiotherapy half pelvis Recovered prior radiotherapy No concurrent anticancer radiotherapy Surgery : See Disease Characteristics Other : At least 4 week since prior investigational therapy recover No concurrent anticancer investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>childhood germ cell tumor</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>childhood teratoma</keyword>
	<keyword>childhood malignant testicular germ cell tumor</keyword>
	<keyword>childhood extragonadal germ cell tumor</keyword>
	<keyword>childhood malignant ovarian germ cell tumor</keyword>
	<keyword>recurrent childhood malignant germ cell tumor</keyword>
</DOC>